 This is a prospective, single center, clinical study of SRT2104 administered orally; a randomized, inpatientoutpatient study to assess the safety and pharmacokinetics PK of SRT2104 in healthy male volunteers. Ten 10 male subjects, aged 18-60, who fulfil the inclusionexclusion criteria, will be enrolled in this study. Subjects will receive either a dose of 2.0 g SRT2104 administered as eight 250 mg capsules or placebo on eight occasions during the study; once as a single dose study day 1 during Treatment Period 1, and once per day for seven consecutive days study days 15 to 21 during Treatment Period 2. Every administration of SRT2104 will be in the fed state i.e. within 30 minutes following the start of consumption of a standard meal. 